Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: A southwest oncology group study

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 664-669

  Margolin, Kim A ^a   Liu, P Y ^a   Flaherty, Lawrence E ^a   Sosman, Jeffrey A ^a   Walker, Michael J ^a   Smith III, John W ^a   Fletcher, William S ^a   Weiss, Geoffrey R ^a   Unger, Joseph M ^a   Sondak, Vernon K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031896003     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.664     Document Type: Article

References (29)

1. Carbone P, Costello W: Eastern Cooperative Oncology Group studies with DTIC (NSC-45388). Cancer Treat Rep 60:1287-1295, 1976
2. Ramirez G, Wilson W, Grage T, et al: Phase II evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU, NSC-409962) in patients with solid tumors. Cancer Treat Rep 56:787-790, 1972
3. McClay EF, Mastrangelo MJ, Berd D, et al: Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials. Int J Cancer 50:553-556, 1992
4. McClay EF, Mastrangelo MJ, Sprandio JD, et al: The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 63:1292-1295, 1989
5. Flaherty LE, Liu PY, Mitchell MS, et al: The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. Am J Clin Oncol 19:108-113, 1996
6. Flaherty L, Liu PY, Smith D, et al: Comparison of patient characteristics and outcome between a single institution and cooperative group phase II trial in metastatic melanoma with identical eligibility. Proc Am Soc Clin Oncol 13:397, 1994 (abstr 1352)
7. McClay EF, Albright KD, Jones JA, et al: Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res 52:6790-6796, 1992
8. McClay EF, Albright KD, Jones JA, et al: Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 53:1571-1576, 1993
9. Cocconi G, Bella M, Calabresi F, et al: Treatment of metastatic malignant with dacarbazine plus tamoxifen. N Engl J Med 327:516-523, 1992
10. Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 3473-3486, 1990
11. Del Prete SA, Maurer LH, O'Donnell J, et al: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68:1403-1405, 1984
12. McClay EF, Mastrangelo MJ, Bellet RE, et al: Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71:465-469, 1987
13. Lattanzi SC, Tosteson T, Cliertoff J, et al: Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 5:365-369, 1995
14. Buzaid AC, Murren JR, Durivage HJ: High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma. Cancer 68:1238-1241, 1991
15. Thomson DB, Walpole ET, Beadle GF, et al: High dose tamoxifen does not enhance the activity of dacarbazine in metastatic melanoma: QMP9105. Proc Am Soc Clin Oncol 12:392, 1993 (abstr 1339)
16. Bajetta E, Zampino MG, Noie F, et al: Tamoxifen does not improve response when added to chemotherapy in metastatic melanoma. An Italian trials in medical oncology. Proc Am Soc Clin Oncol 12:393, 1993 (abstr 1345)
17. Ferri W, Kirkwood JM, Vlock D, et al: Carboplatin (C) and dacarbazine (D) ± tamoxifen (T) for metastatic melanoma. Proc Am Soc Clin Oncol 12:396, 1993 (abstr 1358)
18. Berd D, McLaughlin CJ, Hart E, et al: Short course, high-dose tamoxifen (TAM) with cytotoxic chemotherapy for metastatic melanoma. Proc Am Soc Clin Oncol 10:291, 1991 (abstr 1016)
19. Legha S, Ring S, Bedikian A, et al: Lack of benefit from tamoxifen (T) added to a regimen of cisplatin (C), vinblastine (V), DTIC (D) and alpha interferon (IFN) in patients (PT) with metastatic melanoma (MM). Proc Am Soc Clin Oncol 12:388, 1993 (abstr 1325)
20. Falkson CI, Ibrahim J, Kirkwood J, et al: A randomized phase III trial of dacarbazine (DTIC) versus DTlC + interferon alfa-2b (IFN) versus DTIC + tamoxifen (TMX) versus DTIC + IFN + TMX in metastatic malignant melanoma: An ECOG trial. Proc Am Soc Clin Oncol 15:435, 1996 (abstr 1350)
21. Rusthoven JJ, Quirt IC, Iscoe NA, et al: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14:2083-2090, 1996
22. Fletcher WS, Daniels SD, Sondak VK, et al: Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma. Am J Clin Oncol 16:359-362, 1993
23. Mitchell MS, Von Eschen KB: Phase III trial of Melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma. Proc Am Soc Clin Oncol 16:494, 1997 (abstr)
24. Stark JJ, Schulof R, Wiemann M, et al: Alpha interferon and chemo-hormonal therapy in advanced melanoma: A phase I-II NBSG/MAOP study. Proc Am Soc Clin Oncol 12:392, 1993 (abstr 1341)
25. Feun LG, Savaraj N, Moffat F, et al: Phase II trial of recombinant interferon-α with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. Melanoma Res 5:273-276, 1995
26. Legha S, Plager C, Ring S, et al: A phase-II study of biochemotherapy using interleukin-2 (IL-2) + interferon alfa-2a (IFN) in combination with cisplatin (C), vinblastine (V), and DTIC (D) in patients with metastatic melanoma. Proc Am Soc Clin Oncol 11:343, 1992 (abstr 1179)
27. Richards JM, Mehta N, Ramming K, et al: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10:1338-1343, 1992
28. Khayat D, Borel C, Tourani JM, et al: Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 11:2173-2180, 1993
29. Chiarion Sileni V, Nortilli R, Medici M, et al: BCNU (B), cisplatin (C), dacarbazine (D) and tamoxifen (T) (BCDT) in metastatic melanoma (MM): results of a randomized phase II study. Proc Am Soc Clin Oncol 16:495a, 1997 (abstr 1782)